An Iowa Senate panel advanced a bill that would expand access to psilocybin treatments for post-traumatic stress disorder and treatment-resistant depression. Psilocybin, sometimes referred to as magic mushrooms, is a naturally occurring psychedelic compound found in certain mushrooms. The bill (HF 978) outlines regulations for growing, distributing, and administering the substance for medical use.
Treatment Framework and Supervision
The bill specifies that psilocybin treatments would be supervised and only available to people over 21. According to the legislation, the substance would be available only under medical supervision for those meeting specific diagnostic criteria for PTSD and treatment-resistant depression. The FDA has designated psilocybin treatments for depression as breakthrough therapies, which expedites the review of drugs for serious conditions.
Debate and Opposition
The Iowa Behavioral Health Association opposes the bill. Amy Campbell, a lobbyist for the association, stated that the state should wait until the Federal Drug Administration approves the substance through standard processes. “We think that’s the process that this should go through, rather than creating a separate process in the state to legalize this,” Campbell said.
Supporters’ Arguments
Supporters of the bill argue that making psilocybin legal for medical use will help Iowans and specifically veterans who are struggling with mental health problems that are difficult to treat with current therapeutic options. The bill represents an effort to provide access to emerging treatments for treatment-resistant conditions.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.iowapublicradio.org/state-government-news/2026-03-19/senate-panel-approves-bill-expanding-access-to-hallucinogenic-treatments-in-iowa